Hepatitis C Treatment Cascade in a Federally Qualified Health Center

  • David M. HacheyEmail author
  • John T. Holmes
  • Nicki L. Aubuchon-Endsley
Original Paper


Hepatitis C (HCV) care cascades have been described in diverse clinical settings, patient populations and countries, highlighting the steps in HCV care where improvements can be made and resources allocated. However, more research is needed to examine barriers to HCV treatment in rural, underserved populations and in Federally Qualified Health Centers (FQHCs). As part of a quality improvement (QI) project, this study aimed to describe and evaluate the HCV treatment cascade in an FQHC serving a large rural patient population in the Western United States. Standardized chart abstraction was utilized to aggregate data regarding patient demographics, the percentage of patients achieving each step in the treatment cascade, and relevant patient (i.e., viral load) and service variables (i.e., whether and when patients received treatment or medication). 389 patients were identified as having HCV and 86% were aware of their diagnosis. Fifty-five percent had their infection confirmed via viral load, 21% were staged for liver disease, 24% received a prescription for treatment, and 19% achieved cure. Compared to national data, the current regional sample had greater rates of diagnosis awareness and access to care, as well as sustained virologic response (SVR), but lower rates of viral load confirmation. Current findings suggest that rural patients living with HCV who receive care at FQHCs struggle to navigate the treatment cascade and achieve a cure, particularly with regard to infection confirmation, liver staging, and prescription. However, compared to national estimates, patients had greater rates of diagnosis awareness/treatment access and SVR.


Hepatitis C Care cascade Federally Qualified Health Center Rural health Quality improvement 



This study did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Compliance with Ethical Standards

Conflict of interest

The authors declare no relevant conflicts of interest or financial relationships.


  1. 1.
    AASLD-IDSA. HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Retrieved July 22, 2019 from
  2. 2.
    Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y., Holtzman, D., & Ward, J. W. (2012). Hepatitis C virus testing of persons born during 1945-1965: Recommendations from the Centers for Disease Control and Prevention. Annals of Internal Medicine, 157, 817–822. Scholar
  3. 3.
    Yehia, B. R., Schranz, A. J., Umscheid, C. A., Lo Re, I. I. I., & Lo Re III, V. (2014). The treatment cascade for chronic Hepatitis C Virus infection in the United States: A systematic review and meta-analysis. PLoS ONE, 9(7), 1–7.Google Scholar
  4. 4.
    Kattakuzhy, S., Gross, C., Emmanuel, B., et al. (2017). Expansion of treatment for hepatitis C virus infection by task shifting to community-based nonspecialist providers: A nonrandomized clinical trial. Annals of Internal Medicine, 167(5), 311–318.CrossRefGoogle Scholar
  5. 5.
    Gardner, E. M., McLees, M. P., Steiner, J. T., Del Rio, C., & Burman, W. J. (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases, 52(6), 793–800.CrossRefGoogle Scholar
  6. 6.
    Gvinjilia, L., Nasrullah, M., Sergeenko, D., et al. (2016). National progress toward hepatitis C elimination—Georgia, 2015–2016, MMWR. Morbidity and Mortality Weekly Report, 65, 1132–1135.CrossRefGoogle Scholar
  7. 7.
    Janjua, N. Z., Kuo, M., Yu, A., et al. (2016). The population level cascade of care for hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine, 12, 189–195.CrossRefGoogle Scholar
  8. 8.
    Wade, A. J., Macdonald, D. M., Doyle, J. S., et al. (2015). The cascade of care for an Australian community-based hepatitis C treatment service. PLoS ONE, 10(11), e0142770.CrossRefGoogle Scholar
  9. 9.
    Cachay, E. R., Hill, L., Wyles, D., et al. (2014). The hepatitis C cascade of care among HIV infected patients: A call to address ongoing barriers to care. PLoS ONE, 9(7), e102883.CrossRefGoogle Scholar
  10. 10.
    Mera, J., Vellozzi, C., Hariri, S., et al. (2016). Identification and clinical management of persons with chronic hepatitis C virus infection - Cherokee Nation, 2012-2015. MMWR Morbidity and Mortality Weekly Report, 65(18), 461–466.CrossRefGoogle Scholar
  11. 11.
    Jonas, M. C., Rodriguez, C. V., Redd, J., Sloane, D. A., Winston, B. J., & Loftus, B. C. (2016). Streamlining screening to treatment: The hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States. Clinical Infectious Diseases, 62(10), 1290–1296.CrossRefGoogle Scholar
  12. 12.
    Health Resources & Services Administration. (2018). Health services program. Retrieved July 22, 2019 from
  13. 13.
    Arora, S., Thornton, K., Murata, G., et al. (2011). Outcomes of treatment for hepatitis C virus infection by primary care providers. New England Journal of Medicine, 364(23), 2199–2207.CrossRefGoogle Scholar
  14. 14.
    Camminati, C. W., Simha, A., Kolb, N. R., & Prasad, R. (2016). Intent to build hepatitis C treatment capacity within family medicine residencies: A nationwide survey of program directors: A CERA study. Family Medicine, 48(8), 631–634.Google Scholar
  15. 15.
    Benjamini, Y., & Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 57(1), 289–300.Google Scholar
  16. 16.
    Younossi, Z. M., Stepanova, M., Afendy, M., et al. (2013). Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. Journal of Viral Hepatitis, 20, 550–555.CrossRefGoogle Scholar
  17. 17.
    Moorman, A. C., Gordon, S. C., Rupp, L. B., et al. (2013). Baseline characteristics and mortality among people in care for chronic viral hepatitis: The chronic hepatitis cohort study. Clinical Infectious Diseases, 56, 40–50.CrossRefGoogle Scholar
  18. 18.
    Groessl, E. J., Liu, L., Ho, S. B., et al. (2012). National patterns and predictors of liver biopsy use for management of hepatitis C. Journal of Hepatology, 57, 252–259.CrossRefGoogle Scholar
  19. 19.
    Kanwal, F., Schnitzler, M. S., Bacon, B. R., et al. (2010). Quality of care in patients with chronic hepatitis C virus infection: A cohort study. Annals of Internal Medicine, 153, 231–239.CrossRefGoogle Scholar
  20. 20.
    Kanwal, F., Hoang, T., Chrusciel, T., et al. (2012). Process of care for hepatitis C infection is linked to treatment outcome and virologic response. Clinical Gastroenterology and Hepatology, 10, 1270–1277.CrossRefGoogle Scholar
  21. 21.
    Lubega, S., Agbim, U., Surjadi, M., Mahoney, M., & Khalili, M. (2013). Formal hepatitis C education enhances HCV care coordination, expedites HCV treatment and improves antiviral response. Liver International, 33, 999–1007.CrossRefGoogle Scholar
  22. 22.
    Falade-Nwulia, O., McAdams-Mahmoud, A., Irvin, R., et al. (2016). Primary care providers knowledge, attitude and practices related to hepatitis C screening and treatment in the oral direct acting antiviral agents era. Journal of Community Medicine and Health Education, 6(5), 481.Google Scholar
  23. 23.
    Zickmund, S. L., Brown, K. E., & Bielefeldt, K. (2007). A systematic review of provider knowledge of hepatitis C: Is it enough for a complex disease? Digestive Diseases and Sciences, 52(10), 2550–2556.CrossRefGoogle Scholar
  24. 24.
    Institute for Healthcare Improvement. (2019). Age-friendly health systems: Guide to using the 4Ms in the care of older adults. Retrieved July 8, 2019 from

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Family MedicineIdaho State UniversityPocatelloUSA
  2. 2.Department of PsychologyIdaho State UniversityPocatelloUSA

Personalised recommendations